April 12, 2024

Mercaptopurine: A Cornerstone in Treating Childhood Acute Lymphoblastic Leukemia

Mercaptopurine, often referred to by its chemical name 6-mercaptopurine or simply 6-MP, stands as a pivotal medication in the oncology sphere, particularly within the context of treating childhood Acute Lymphoblastic Leukemia (ALL).
February 26, 2024

Effect of Mannitol Hydration on Cisplatin-Induced Nephrotoxicity

Mannitol is used after cisplatin treatment to prevent or reduce the risk of cisplatin-induced nephrotoxicity, which is a major concern associated with cisplatin chemotherapy. Cisplatin is a widely used chemotherapeutic drug for various types of cancer, but its use is often limited by its potential to cause kidney damage.
February 24, 2024

The Role of Heparin in Cancer Treatment: Managing Venous Thromboembolism and Chemotherapy in Patients with Pancreatic Cancer

Heparin, available as both unfractionated and low-molecular-weight forms, has been extensively studied for its potential benefits in cancer patients. Low molecular weight heparin's role in both preventing and treating venous thromboembolism in patients, a common complication in cancer patients, has been the subject of systematic review and numerous randomized clinical trials. Furthermore, heparin has shown promising effects in managing VTE in patients undergoing cancer therapy, including those with advanced pancreatic cancer.
February 7, 2024

Unlocking the Potential of Enhertu: A Revolutionary Advance in Targeted Cancer Therapy

The development of Enhertu represents a significant advancement in targeted cancer therapy, offering new hope for patients with limited treatment options. Enhertu, also known as trastuzumab deruxtecan, is an innovative antibody-drug conjugate (ADC) designed to target HER2-positive cancers, which are associated with aggressive growth and poor prognosis in various cancer types, including breast and gastric cancers
January 22, 2024

Pluvicto: Most Asked Questions

"for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy."
January 19, 2024

Why Atezolizumab and Chemotherapy Should Be Used with Caution in Real-World SCLC Population

Atezolizumab, a programmed death-ligand 1 (PD-L1) inhibitor, has shown promising results in clinical trials when combined with chemotherapy for the treatment of extensive-stage small cell lung cancer (ES-SCLC). However, a real-world evaluation of atezolizumab plus platinum-etoposide chemotherapy in patients with ES-SCLC in Canada raises important considerations regarding its use.
Oncology Protocols Pairing
This website uses cookies to improve your experience. By using this website you agree to our Cookie Policy.
Read more